Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (3148)	3/20/2001 8:10:18 PM
From: Ian@SI	Respond to of 52153

Re bad data disclaimer: CRGN would be out of date due to the infusion of cash associated with the Bayer agreements since the end of last year.

To: keokalani'nui who wrote (3148)	3/20/2001 8:17:36 PM
From: Biotech Jim	Respond to of 52153

OK, folks, you have now convinced me and the science has convinced me even more so. I have used up much of my cash over the past two months, and that was built up over the past 6 months. In fact, I will now start to cash in some of my big pharma shares. The bargains abound, and I will start to average in, in some of the biotechs. Some of the biotechs have a better upside potential than that of PFE and PHA, my solid big pharma holdings. My first pick in this recent carnage, as of today, is and will continue to be CVTX. Thanks to several of my cyberbuds for helping me do my DD on this fine cardiovascular company with strong and competent leadership. I am now looking into the genomics companies, and aside from my current holdings in MLNM, am considering several others. Tops on my list are ABGX, MEDX and LEXG. I think these may still be weak in the short term, but selling at 2x cash? This is close to being unprecedented. As they say, the momentum pendulum has swung the opposite way and this represents a buying opportunity. BJ